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The human INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16
INK4a and p14 ARF (p19 ARF in the mouse), which are frequently inactivated in human cancer. Both the proapoptotic and cell cycleregulatory functions of p14 ARF were initially proposed to be strictly dependent on a functional p53/mdm-2 tumor suppressor pathway. However, a number of recent reports have implicated p53-independent mechanisms in the regulation of cell cycle arrest and apoptosis induction by p14 ARF . Here, we show that the G1 cell cycle arrest induced by p14 ARF entirely depends on both p53 and p21 in human HCT116 and DU145 carcinoma cells. In contrast, neither loss of p53 nor p21 impaired apoptosis induction by p14 ARF as evidenced by nuclear DNA fragmentation, phosphatidyl serine exposure, and caspase activation, which included caspase-3/7-and caspase-9-like activities. However, lack of functional p21 resulted in the accumulation of cells in G2/M phase of the cell cycle and markedly enhanced p14 ARF -induced apoptosis that was, nevertheless, efficiently inhibited by the cell permeable broad-spectrum caspase inhibitor zVAD-fmk (valyl-alanylaspartyl-(O)-methyl)-fluoromethylketone). Thus, loss of cell cycle restriction point control in the absence of p21 may interfere with p14 ARF -induced apoptosis. Finally, these data indicate that the signaling events required for G1 cell cycle arrest and apoptosis induction by p14 ARF dissociate upstream of p53.
Introduction
The mammalian INK4a locus encodes two structurally unrelated proteins, the cyclin-dependent kinase inhibitor p16
INK4a and p14 ARF (termed p19 ARF in the mouse), latter of which is transcribed in an Alternative Reading Frame from a separate exon 1b (Duro et al., 1995; Mao et al., 1995; Quelle et al., 1995; Stone et al., 1995) . P14
ARF is usually expressed at low levels, but rapid upregulation of p14 ARF is triggered by various stimuli, that is, the expression of cellular or viral oncogenes including E2F-1, E1A, c-myc, ras, and v-abl (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998; Zindy et al., 1998) . In turn, induction of p14 ARF mediates the accumulation of p53 via sequestration and subsequent degradation of its natural antagonist mdm-2 through the ubiquitin/proteasome pathway (Pomerantz et al., 1998; Stott et al., 1998) . This prolongation of p53 halflife leads to the activation of its downstream target genes such as p21 and Bax (Sherr, 2001) . Thus, activation of the p14 ARF /p53 signaling cascade is viewed as an important fail-safe mechanism that protects cells from excessive and uncontrolled growth triggered through hyperproliferative stimuli (Voorhoeve and Agami, 2003; Zindy et al., 2003) . Consequently, p14 ARF was recognized as potent tumor suppressor as functional inactivation of p14 ARF accelerates tumorigenesis and promotes chemoresistance by disabling p53 (Eischen et al., 1999; Schmitt et al., 1999) .
In contrast to the initial notion that most if not all biological activity of p14 ARF depends on a functional p53/mdm-2 signaling axis, a number of recent reports indicate that p14 ARF as well as its murine homologue p19 ARF and p53 act in overlapping pathways rather than in a strictly sequential manner (Carnero et al., 2000) . Consequently, murine p19 ARF was shown to cause a G1 cell cycle arrest independently from p53, mdm-2, and Rb, as well as p21 (Modestou et al., 2001 ) and p27 (Groth et al., 2000) . In the same vein, we demonstrated that apoptosis induction by p14 ARF is independent from p53 and Bax (Hemmati et al., 2002) . Furthermore, a genome-wide screen identified a number of genes putatively involved in the p53-independent regulation of cellular proliferation by p19 ARF (Kuo et al., 2003) . Most intriguingly, it was reported recently that c-Myc, itself a potent trigger of p14 ARF (p19 ARF ) expression, is part of a p53-independent inhibitory feedback loop (Qi et al., 2004) .
Therefore, we aimed at further investigating and dissecting the signaling pathways involved in cell cycle arrest and apoptosis induction by p14 ARF . To this end, we employed the colorectal cancer cell line HCT116 and its isogeneic sublines homozygously deleted for either p53 (HCT116-p53
), the two key regulators of cell cycle arrest and cell death. We show here that the arrest in G1 phase of the cell cycle upon expression of p14 ARF strictly depends on the presence of both p53 and p21. In contrast, p14 ARF -mediated apoptosis is not impaired upon deletion of either p53 or p21, involves the activation of caspases including caspase-3/7-and caspase-9-like activities, and is subject to inhibition by zVAD-fmk (valyl-alanylaspartyl-(O)-methyl)-fluoromethylketone). Similarly, p53-mutated, p21-deficient DU145 prostate cancer cells were not impaired in their ability to undergo apoptotic cell death upon p14 ARF expression. Notably, loss of p21 resulted in the accumulation of cells in G2/M phase of the cell cycle and markedly enhanced p14 ARF -induced apoptosis. This delineates a novel aspect of p14 ARF -induced cell death, which may be substantially augmented in the absence of proper G1 restriction point control by loss of p21.
Results

Apoptosis induction by p14
ARF is not impaired by loss of p53 and/or p21
In contrast to the initial notion that most if not all p14 ARF activity strictly depends on a functional p53/ mdm-2 signaling axis, a number of recent reports established that p14 ARF is capable of mediating p53-independent effects as well. To investigate this discrepancy and to further dissect the p14 ARF signaling cascade, we employed a previously constructed and functionally characterized adenoviral vector system (Ad-p14 ARF ) for the transient expression of p14 ARF in a number of genetically well-defined cell lines. These included HCT116 colorectal cancer cells lacking either p53 or p21 and DU145 prostate cancer cells carrying distinct defects in p53 and p21.
To this end, HCT116 parental cells wild type for both p53 and p21 (HCT116-WT) and the isogeneic sublines homozygously deleted for either p53 (HCT116-p53
) were transduced with Adp14 ARF and assayed for transgene expression and activation of the p53 pathway (Figure 1 ). Expression of p14 ARF was detectable by immunofluorescence in all HCT116 sublines 24 h after infection with 25 MOI of Ad-p14 ARF ( Figure 1a ). While the localization within the cytoplasm was diffuse, a speckled nuclear expression pattern was detectable. Western blot analysis (Figure 1b) showed an increase in the expression of p53 and p21 in HCT116-WT cells upon expression of p14 ARF . In contrast, HCT116-p53 À/À cells completely lacked the expression of p53 and induction of p21, respectively. Notably, HCT116-p21 À/À cells showed a constitutively elevated p53 expression level but, as expected, were completely void of p21.
Whereas an arrest in G1 phase of the cell cycle upon expression of p14 ARF entirely depends on the presence of p53 (and p21, see below), recent studies indicate that p53 is dispensable for the induction of p14 ARF -triggered apoptotic cell death (Hemmati et al., 2002; Eymin et al., 2003) . To demonstrate that apoptosis induction by p14 ARF is indeed independent from p53, apoptotic DNA fragmentation ( Figure 2 ) and activation of caspases ( Figure 3) were studied in p53-proficient versus p53-deficient HCT116 cells. To this end, HCT116-WT and HCT116-p53 À/À cells were transduced with Ad-p14 ARF in parallel with mock-treated (control) or control vectorinfected (Ad-lacZ) cells and subjected to flow-cytometric analysis of DNA fragmentation 72 h after infection. As shown in Figure 2a , expression of p14 ARF induced apoptotic DNA fragmentation, that is, cells displaying a sub-G1 DNA content, in both p53-proficient and p53-deficient HCT116-WT cells to an identical extent. This effect increased in a dose-dependent manner irrespective of the presence or absence of p53 ( Figure 2b ). Similarly, there was no difference in the induction of pancaspase activities by p14 ARF in both HCT116 sublines (Figure 3a and b), indicating that p14 ARF -induced apoptosis is independent from p53. To corroborate that apoptosis induction by p14 ARF is p53 independent, DU145 prostate cancer cells, which are p53 mutated and p21 deficient, were infected with Ad-p14 ARF and subjected to flow-cytometric detection of apoptotic DNA fragmentation (Figure 4a and b) . In analogy to HCT116 cells, we observed a dose-dependent increase in the number of apoptotic cells ( Figure  4a ), which was initiated at 48 h and reached substantial levels at 72-96 h after transduction with Ad-p14 ARF ( Figure 4b ). In parallel, a dose-dependent increase of pancaspase activities was detected in DU145 cells 72 h after infection ( Figure 4c ). As depicted in Figure 4d , caspase activation occurred between 48 and 72 h after transduction with Ad-p14 ARF and further increased after 96 h. This underscores the notion that p14 ARF -induced apoptosis is independent from p53.
Loss of p21 sensitizes to apoptosis induction by p14 ARF Data obtained in p53-deficient DU145 and HCT116 cells indicated that p14 ARF induces apoptosis irrespective of the presence or absence of functional p53. Furthermore, lack of p21 induction in either cell line suggests that p14 ARF -triggered apoptosis is p21 independent. To further address this issue, we investigated p21-deficient HCT116 cell in parallel with p21-proficient HCT116-WT cells. Interestingly, we observed that loss of p21 strongly augmented the extent of apoptosis induction by p14 ARF when nuclear DNA fragmentation was investigated by flow cytometry (Figure 5a and b) . At 100 MOI, p14 ARF induced genomic DNA fragmentation in approximately 50% of the p21-proficient HCT116 wildtype cells, whereas in HCT116-p21 À/À cells, a level of 70% cells displaying fragmented nuclear DNA was reached. When pancaspase activities were determined by the use of VAD-FITC (Figure 6a and b To substantiate that the activation of caspases is essential for p14 ARF -induced cell death, apoptosis induction by p14 ARF was studied in the presence or absence of the cell-permeable, broad-spectrum caspase ARF was visualized by immunofluorescence using a rabbit polyclonal anti-p14 ARF antibody followed by Alexa fluor 488-conjugated goat-anti-rabbit IgG. Nuclei were counterstained with DAPI. Representative high-power fields from three independent experiments are shown. (b) HCT116 cells either wild type or homozygously deleted for p53 or p21 were mock treated or transduced with the adenoviral constructs Ad-p14 ARF or Ad-lacZ as indicated at an MOI of 25. Cells were harvested 48 h after infection and 20 mg of total cellular proteins were subjected to SDS-PAGE and studied by Western blot analysis for the expression of p14 ARF , p53, and p21. Equal loading was confirmed by reprobing with an antibody against b-actin p21 in p14 ARF -induced cell cycle arrest and apoptosis PG Hemmati et al inhibitor zVAD-fmk ( Figure 7 ). To corroborate that cell death is apoptotic, we employed measurement of phosphatidyl serine exposure on the outer leaflet of the cell membrane by the use of Annexin-V-FITC/propidium iodide (PI) double staining. As shown in Figure 7a and b, expression of p14 ARF resulted in a substantial increase in the number of early apoptotic, that is, Annexin-V-FITC-positive/PI-negative, and necrotic, PI-positive cells as compared to mock-(control) or control vectorinfected (Ad-lacZ) cells 48 h after infection with Adp14 ARF . As expected, cells lacking p21 were again more sensitive as compared to HCT116-WT cells. In the presence of zVAD-fmk, a marked decrease in phosphatidyl serine exposure (Figure 7b ) was observed. Notably, zVAD-fmk also reduced the occurrence of Annexin-V-FITC-positive/PI-positive cells, suggesting that these cells are late apoptotic rather than a priori necrotic. Finally, zVAD-fmk-mediated reduction in apoptotic DNA fragmentation (Figure 7c ) to near background levels was observed in both HCT116-WT and HCT116-p21
. Taken together, these data indicate that p14 ARF induces caspase-dependent apoptotic cell death, which is enhanced by loss of p21.
Induction of caspase activation by p14 ARF
Apoptosis induction by p14
ARF involves the activation of caspases as indicated by a dose-dependent increase in pancaspase activities and inhibition of apoptosis induction by the broad-spectrum caspase inhibitor zVAD-fmk. To differentiate pancaspase activities, HCT116-WT, HCT116-p53
, and HCT116-p21 À/À cells were infected with 100 MOI Ad-p14 ARF in parallel with mock-treated (control) or control vector-infected (Ad-lacZ; 100 MOI) cells and assayed for the activation of caspase-3/7-like caspases by the use of a fluorescent derivative of the caspase-3/7-like caspase inhibitor DEVDfmk (aspartyl-glutamyl-valyl-aspartyl-(O)-methyl)-fluoromethyl-ketone) ( Figure 8 ). The topoisomerase IIa inhibitor epirubicin served as a positive control and was used at a final concentration of 2 mg/ml. As depicted in Figure 8a and b, p14 ARF induced caspase-3/7-like activities in all HCT116 sublines 72 h after infection. In analogy to the cell death data shown in Figures 2 and 3, this effect occurred in a p53-independent manner but was enhanced in the absence of p21. In contrast, epirubicin-induced activation of caspase-3/7-like activity was reduced in p53-deficient, but not altered in p21-deleted HCT116 cells. Similarly, -induced activation of caspase-9-like activity did not differ between p53-proficient and p53-deficient cells, biallelic deletion of p21 strongly enhanced LEHDase activity. Again, epirubicin-induced caspase-9-like LEHDase activity was markedly reduced in p53-deficient versus p53-proficient cells. These data suggest that activation of caspase-3/7 (and other DEVDases) as well as caspase-9 (and other LEHDases) plays an important role in mediating p14 ARF -induced apoptosis. p14 ARF -induced G1 arrest depends on p53 and p21
To determine the impact of p14 ARF on cell cycle arrest, HCT116-WT, HCT116-p53 À/À , and HCT116-p21
À/À cells were transduced with 25 MOI Ad-p14 ARF and assayed for cell cycle distribution after 48 h. As shown in Figure 9a , expression of p14 ARF induced an arrest in G1 phase of the cell cycle in cells proficient for both p53 and p21, that is, HCT116-WT. In contrast, HCT116-p53 À/À and HCT116-p21 À/À cells did not arrest in G1 phase of the cell cycle. Whereas HCT116-WT cells showed a corresponding decrease in the number of cells in S phase, the proportion of S phase cells remained mostly unchanged in cells deficient for either p53 or p21. Consequently, the relative number of cells in G2/M phase of the cell cycle increased in the absence of either p53 or p21. The accumulation of cells in G1 phase of the cell cycle upon expression of p14 ARF occurred in a dose-dependent manner only in p53/p21-proficient HCT116-WT cells (Figure 9b ). In contrast, a dose-dependent decrease of cells in G1 phase of the cell cycle upon expression of p14 ARF was observed in cells homozygously deleted for either p53 or p21. These results clearly indicate that the induction of G1 cell cycle arrest by p14 ARF depends on a functional p53/p21 signaling axis.
Inhibition of DNA synthesis by p14
ARF is independent from p53 and p21 The results described above strongly suggest that p14 ARF -induced G1 arrest strictly depends on the presence of both p53 and p21. Yet, several lines of evidence indicate that p14 ARF is capable of inhibiting cell cycle progression as well via p53-independent mechanisms (Eymin et al., 2001; Martelli et al., 2001 ). Therefore, we tested the impact of p14 ARF expression on DNA synthesis in cells either proficient (HCT116-WT) or deficient for p53 (HCT116-p53
). To this end, HCT116-WT, HCT116-p53
, and ARF -mediated G1 arrest is paralleled by inhibition of DNA synthesis, which is independent from the presence or absence of functional p53 or p21.
Discussion
It is still a matter of debate whether the induction of cell cycle arrest and apoptosis by p14 ARF equally depend on an intact p53/mdm-2 signaling axis. Data from initial reports indicated a functional role of both p53 and p21 as a strict prerequisite for 14 ARF -mediated cell cycle arrest. Nevertheless, a number of follow-up studies clearly demonstrated that this is not entirely the case. In particular, distinct members of E2F family of transcription factors were suggested to be critical downstream targets of p53-independent growth arrest programmes engaged by p14 ARF (Eymin et al., 2001; Martelli et al., 2001; Mason et al., 2002; Rowland et al., 2002) . Furthermore, a delay in S-phase progression with consecutive accumulation of cells in G1 phase of the cell cycle upon expression of p14 ARF was shown to occur independently of p53 (Yarbrough et al., 2002) . Similarly, others have shown that a replicative senescence-like type of G1 arrest may be induced by the prolonged expression of p19 ARF in mouse embryonic fibroblasts regardless of p53 and p21 function (Carnero et al., 2000; Weber et al., 2000) , and in the absence of mdm-2. In the same vein, we recently showed that forced expression of p14 ARF induces apoptosis in p53/Bax-deficient cells (Hemmati et al., 2002) . In contrast, genetic evidence from murine knockout models strongly suggested that p19 ARF is capable of regulating cellular proliferation in a p53-independent manner (Eischen et al., 1999; Weber et al., 2000) . Most intriguingly, the c-Myc oncoprotein was recognized recently as a key factor in regulating p19 ARF -mediated proliferative effects in a p53-independent manner (Qi et al., 2004) . By serving as a direct transcriptional target, p19 ARF differentially regulates the c-Myc's transactivating and transrepressing function. Although not fully understood yet, it is now widely recognized that both the induction of cell cycle arrest and apoptosis by p14 ARF involve a much more complex network of intracellular signaling events than initially thought (Cleveland and Sherr, 2004) . In particular, the fact that an arrest in G1 phase of the cell cycle is entirely dependent on functional p53 (Weber et al., 2002) , whereas the induction of apoptotic cell death is not suggests that the two signaling cascades are, at least in part, independent.
In the present work, we show that p14 ARF triggered an arrest in the G1 phase of the cell cycle that strictly depends on both functional p53 and p21. In contrast, p14 ARF -induced apoptosis was not impaired in tumor cells with disrupted p53/p21 but was even enhanced upon targeted knockout of the p21 gene, that is, in 
HCT116 -p21
À/À cells. This indicates that cell cycle arrest and apoptosis induction by p14 ARF proceed through distinct signaling events that dissociate upstream of p53.
Regarding cell cycle regulation, HCT116 wild-type cells rapidly arrested preferentially in G1 phase of the cell cycle within 24-48 h upon expression of p14 ARF . In contrast, isogeneic HCT116 cells homozygously deleted for either p53 or p21 did so to a far lesser extent but, instead, accumulated in G2/M. To confirm these results, we employed the prostate cancer cell line DU145, which is characterized by mutated, functionally inactive p53, resulting in a failure to induce p21 expression (Hemmati et al., 2002) . Similar to HCT116 cells that are homozygously deleted for either p53 or p21, DU145 cells failed to arrest in G1 phase of the cell cycle after expression of p14 ARF . Instead, like HCT116-p53 À/À and HCT116-p21 À/À cells, the accumulation of cells in G2/M phase of the cell cycle was observed. These data confirm the notion that the p14 ARF -induced G1 arrest is entirely dependent on the presence of functional p53 and its downstream effector p21. Furthermore, our data indirectly suggest that the absence of p53 cannot be readily compensated by other p53 homologues such as p63 and p73. Moreover, this indicates that the propensity to undergo G2/M arrest neither relies on p53 nor p21. In contrast, it was recently suggested that the p14 ARF -induced G2 arrest occurs through a p21-dependent pathway in p53-deficient cells (Eymin et al., 2003) . Our data indicate, however, that a G1 arrest via the p53-mediated induction of p21 represents the dominant arrest program triggered by p14 ARF , whereas G2/M arrest and the previously described S-phase delay , and DU145 indicate that loss of p53 and p21 does not affect the propensity of p14 ARF to arrest cells in G2/M phase of the cell cycle. Consequently, we recently showed that this G2 arrest induced by p14 ARF is mediated by inhibition of the the p34 cdc2 (cdk-1) kinase through an entirely p53/p21-independent mechanism (Normand et al., 2004) . Whereas these data indicate that p14 ARF regulates cdc2-kinase activity at the post-translational level, that is, through interference with protein turnover or subcellular localization, further studies are necessary to clarify the mechanism of cdc2 targeting by p14 ARF that, however, does not appear to involve direct physical interaction with and sequestration via p14 ARF . In contrast, recent reports have suggested other mechanisms by which p14 ARF may bypass p53-induced p21 in p14 ARF -induced cell cycle arrest and apoptosis PG Hemmati et al G1 cell cycle arrest. These include the binding, sequestration, and functional inactivation of E2F transcription factors necessary for cells to enter and progress through S phase (Eymin et al., 2001; Martelli et al., 2001; Rowland et al., 2002) among other factors involved in DNA replication (Yarbrough et al., 2002) . Indeed, by inhibition of S-phase entry and progression, cells may accumulate in G1 phase of the cell cycle. This may serve well to explain the fact that in some studies a G1 arrest was observed in cells lacking functional p53 or carrying a disruption of the Rb pathway. However, the relevance of such p53-independent modes of p14 ARF -induced G1 arrest remains to be established. In contrast to p14 ARF -induced cell cycle arrest in G1, apoptosis is triggered through a distinct, p53-and p21-independent mechanism. The mitochondrial pathway of apoptosis is initiated by a number of different stimuli including DNA damage or the activation of cellular and viral oncogenes (Daniel, 2000; Daniel et al., 2003; Gu¨ner et al., 2003) . In contradiction to the initial notion that apoptosis induction by p14 ARF relies on a functional p53/mdm-2 rheostat, we recently showed that p14 ARF is capable of triggering the mitochondrial pathway of apoptosis followed by the activation of caspases, independently from the presence or absence of functional p53 and Bax (Hemmati et al., 2002) . In continuation of this work, we show here that induction of apoptosis by p14 ARF is not hampered by disruption of p53 or p21. This was evidenced by nuclear DNA fragmentation, which was preceded by caspase activation and phosphatidyl serine exposure on the cell surface, that is, Annexin-V positivity. Moreover, we establish that loss of p21 substantially augments p14 ARF -induced apoptosis, suggesting that p21 is not required for apoptosis induction as has been reported in other experimental systems before (Fotedar et al., 1999) . In view of the strict dependence of p14 ARF on p53 and p21 to mediate G1 arrest, our data delineate that the induction of apoptosis and cell cycle arrest by p14 ARF occurs through separate signaling pathways that dissociate upstream of p53 (Figure 11) . Thus, loss of p53 and its transcriptional target p21 does not impair the induction of apoptosis but abrogates p14 ARF -induced G1 arrest. Nevertheless, p21 appears to play a regulatory role in p14 ARF -induced cell death. Hence, the acceleration of p14 ARF -induced apoptosis in the absence of p21 may indicate a critical role for cell cycle arrest programs in p14 ARF -triggered cell death. Such an inhibitory function of p21 was described earlier for DNA damage responses, where loss of p21 sensitized carcinoma cells for apoptosis both in vitro (Waldman et al., 1995) and in vivo in human disease (Rau et al., 2003) . This, in fact, makes sense when considering the induction of cell death by p14 ARF during oncogenic transformation. There, disruption of p53 and consecutive impairment of p21 signaling may have deleterious consequences and sensitization for p14 ARF -induced apoptosis upon loss of p21 might counterbalance such events.
It is worth noting that expression data in the p21
and p53 À/À cells seem to indicate that p21 and p53 may also negatively regulate each other as loss of p21 results in higher levels of p53 protein (Figure 1 ). However, both p53-dependent and p53-independent apoptosis were shown to be sensitized for by loss of p21. Indeed, defects in p53-dependent induction of p21, repression of p53-dependent induction of p21 transcription, or caspase-mediated cleavage of p21 may result in increased p53-dependent apoptosis (Bissonnette and Hunting, 1998; Zhang et al., 1999; Kokontis et al., 2001) . Therefore, increased expression of p53 may sensitize for apoptosis induction by p14 ARF , that is, via activation of downstream target genes. In turn, a number of reports delineate that p21 is a negative regulator of p53-independent apoptosis. Here, enhancement of apoptosis, that is, as induced by TGF-b, TNFa, histone deacetylase inhibitors, and IFN-g was observed by loss of p53-independent transctivation of p21 (Donato and Perez, 1998; Zhu et al., 1998; MahyarRoemer and Roemer, 2001; Pennington et al., 2001) . Experiments are therefore underway to further dissect the mechanisms of p21-enhanced apoptosis induction by p14 ARF in relation to p53 and cell cycle checkpoint disruption. Nevertheless, p53-independent induction of apoptosis by p14 ARF has now been shown not only by our group (Hemmati et al., 2002) but also by others (Eymin et al., 2003) .
Apoptosis induction by p14 ARF involves a breakdown of mitochondrial membrane potential followed by the activation of caspases, which is independent from the presence or absence of functional p53 and Bax (Hemmati et al., 2002) . Here, we provide additional evidence that p14 ARF -induced apoptosis activates the mitochondrial apoptosis pathway as indicated by the activation of caspase-9-like LEDHase activities. In Figure 11 Dissociation of cell cycle arrest and apoptosis induction by p14
ARF occurs upstream of p53. The presence of both p53 and p21 is strictly required to arrest cells in G1 phase of the cell cycle upon expression of p14 ARF . In contrast, induction of apoptosis by p14 ARF is not impaired upon loss of p53 or p21. Previous data established that this type of cell death is independent from Bax. However, loss of p21 enhances apoptosis sensitivity upon expression of p14
ARF . This delineates that the activation of p21-mediated checkpoint control by p14 ARF interferes with p14 ARF -induced apoptosis signaling p21 in p14 ARF -induced cell cycle arrest and apoptosis PG Hemmati et al analogy to DNA fragmentation and pancaspase activity, these caspase-9-like activities were greatly enhanced in cells lacking functional p21. In contrast, activation of caspase-3/7 and caspase-9-like activities by the topoisomerase IIa poison epirubicin was substantially reduced in p53-deficient cells, underscoring the notion that drug-induced apoptosis, at least in part, depends on functional p53, whereas p14 ARF -induced apoptosis is entirely p53 independent.
Materials and methods
Cell culture
HEK293 and DU145 were obtained from the ATCC (Manassas, VA, USA) or the DSMZ (Braunschweig, Germany). HCT116 wild-type cells and their isogeneic knockout sublines HCT116-p21 À/À (Waldman et al., 1995) and HCT116-p53 À/À (Bunz et al., 1998) were kindly provided by Dr Bert Vogelstein, Johns Hopkins Cancer Center, Baltimore, MD, USA. For the HCT116-p53
, we employed clone 379.2 that, in contrast to another HCT116-p53 À/À clone employed in a previous report of our group, has the propensity to undergo apoptotic DNA fragmentation. HEK293 and DU145 cells were grown in DMEM/high glucose (4.5 g/l) medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (all from Invitrogen, Karlsruhe, Germany). HCT116 cells were cultured in McCoy's 5A medium (Invitrogen) supplemented with 10% FCS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin.
Construction of recombinant adenoviral vectors
Ad5-CMVp14
ARF (Ad-p14 ARF ) was constructed as described previously (Hemmati et al., 2002) and high-titer stocks of recombinant adenovirus were generated according to standard procedures as described (Gillissen et al., 2003) . An adenovirus for the expression of b-galactosidase (Ad-lacZ) was used as a control. Transduction efficiency was tested in a number of cell lines (including DU145 and HCT116) by infection with the Ad-lacZ control virus. Cells were maintained at 371C with 5% CO 2 in a fully humidified atmosphere and infected with adenoviral vectors diluted in DMEM/high glucose in the absence of FCS or antibiotics at the indicated MOI for 2 h at 371C or were mock treated with serum-free medium only.
Antibodies and reagents
Mouse monoclonal anti-p14 ARF antibody (clone 14P02, raised against full-length recombinant human p14 ARF protein) was purchased from NeoMarkers (Freemont, CA, USA). Antibodies against p21 (clone 6B6, raised against a fusion protein between GST and full-length human p21) and p53 (clone DO-1, reactive against amino acids (aa) 1-45 of human p53) were both murine monoclonal antibodies purchased from BD-Pharmingen (Heidelberg, Germany) used at dilution of 1 : 1000. An antibody against b-actin (Sigma-Aldrich, St Louis, MI, USA, reactive against an 11 aa C-terminal actin fragment) was a rabbit polyclonal antibody used at a dilution of 1 : 500. All antibodies were diluted in phosphate-buffered saline (PBS) supplemented with 0.05% Tween-20 (PBS-T), 3% nonfat dry milk, and 0.1% NaN 3 . Secondary goat-anti-mouse IgG and goat-anti-rabbit IgG antisera coupled to horseradish peroxidase from Promega (Madison, WI, USA) were used at a dilution of 1 : 5000 in PBS-T.
Immunofluorescence
Immunofluorescence was performed as described previously (Weber et al., 2002) . Briefly, 1.5 Â 10 5 cells were seeded on sterile coverslips, grown for 24 h, and infected with adenoviral vectors at the indicated MOI for 24 h. After three washes with PBS, cells were fixed with 50% acetone/methanol (v/v) for 15 min and air-dried. After permeabilization with 0.1% NP-40 in PBS for 10 min, slides were incubated with blocking solution (PBS supplemented with 2% BSA) for 40 min prior to incubation with an anti-p14 ARF antibody in blocking solution at room temperature on a shaker for 1 h. After three washes in PBS, slides were incubated with an Alexa fluor 488-labeled anti-rabbit antibody (Molecular Probes, Leiden, The Netherlands) for 2 h. Finally, slides were washed and mounted with Mowiol solution (Merck, Bad Soden, Germany) containing DAPI (Sigma-Aldrich) at a final concentration of 0.5 mg/ml.
Immunoblotting
Cells were harvested by trypsinization, washed twice with icecold PBS, and lysed in appropriate amounts of lysis buffer (10 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5mM EDTA) supplemented with protease inhibitors (1 mM pepstatin, 1 mM leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride) for 30 min on ice. Samples were then centrifuged at 15 000 g for 15 min at 41C and the concentration of total cellular proteins from the supernatants was determined using the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Thereafter, samples were mixed with sample buffer (125 mM Tris-HCl, 288 mM b-mercaptoethanol, 20% glycerol, 2% SDS, 10 mg/ml bromophenol blue), boiled for 5 min, and equal amounts of protein (20 mg) were separated by SDS-PAGE using 16 or 10% gels, respectively. Immunoblotting and visualization of the proteins using enhanced chemiluminescence were performed as described (Hemmati et al., 2002) . For control of equal protein loading, membranes were reprobed with an antibody against b-actin.
Cell cycle analysis and measurement of apoptotic cell death
In all, 5 Â 10 5 cells were seeded per 75 cm 2 flask (Costar, Cambridge, MA, USA), cultured overnight, and infected with adenoviral vectors as indicated. At the indicated time points, cells were harvested and cell cycle analysis was performed on the single-cell level by measuring the DNA content of individual cells by flow cytometry as described (Daniel et al., 1999) . Analysis was carried out with a linear amplification in the FL-2 channel of a FACScan flow cytometer (BDPharmingen) equipped with the CellQuestPro software and quantified by the use of ModFit. Apoptosis was determined on the single-cell level by measuring the DNA content of individual cells with a logarithmic amplification in the FL-3 channel of a FACScan flow cytometer (BD-Pharmingen) equipped with the CellQuestPro software as described (Hemmati et al., 2002) . Data are given in percent hypoploidy (i.e. the percentage of cells with a sub-G1 DNA content), which reflects the percentage of apoptotic cells with fragmented genomic DNA. In addition, apoptosis was determined by flow-cytometric detection of Annexin-V-FITC (BD-Pharmingen, San Diego, CA, USA) binding to phosphatidyl serine groups exposed at the outer leaflet of the cell membrane as described (Scholz et al., 2002) . Treatment with the topoisomerase IIa inhibitor epirubicin (Pharmacia, Erlangen, Germany) at a final concentration of 2 mg/ml was used as a positive control for apoptosis induction. For inhibition of apoptosis, the cell permeable broad-spectrum caspase inhibitor zVADfmk (Bachem, Bubendorf, Switzerland) was added at a final concentration of 40 mM to the individual samples 2 h after adenoviral infection.
BrdU incorporation
Cells were seeded into six-well plates at 1 Â 10 5 cells/well, cultured overnight, and infected with adenoviral vectors. Prior to harvest, cells were pulse labeled with BrdU (Sigma-Aldrich) at a final concentration of 10 mM in the culture medium for 30 min. Analysis of DNA synthesis, that is, incorporation of BrdU across the cell cycle, was performed as described (Craig et al., 1998 ) using a fluorescein-isothiocyanate (FITC)-labeled monoclonal antibody against BrdU (BD-Pharmingen). The percentage of BrdU-positive cells is given and represents cells in S phase.
Detection of caspase activation on the single-cell level Measurement of caspase activation by the use of an FITClabeled conjugate of the cell-permeable pancaspase inhibitor VAD-fmk from Promega was performed as described (Hemmati et al., 2002) . Activation of caspase-3/7-like caspases (DEVDases) was detected by the use of a carboxyfluorescein (FAM)-labeled derivative of the cell permeable caspase-3/7-like inhibitor DEVD-fmk from Immunochemistry Technologies, MN, USA. Caspase-9-like caspase activities (LEHDases) were detected by using a cell-permeable, FAM-labeled derivative of LEHD-fmk (leucyl-glutamyl-histidyl-aspartyl-(O-methyl)-fluoromethyl-ketone) (Immunochemistry Technologies). After infection with recombinant adenovirus, cells were harvested and washed twice in PBS. Equal numbers of cells (5 Â 10 5 ) were resuspended in 100 ml PBS supplemented with FITC-VAD-fmk, FAM-DEVD-fmk, or FAM-LEHD-fmk at a final concentration of 10 mM for 30 min at 371C with moderate shaking. Thereafter, cells were collected by centrifugation, washed twice with PBS, and finally resuspended in 200 ml PBS. Caspase activation was quantified by flowcytometric detection of cells with increased fluorescence, that is, through binding of FITC-VAD-fmk, FAM-DEVD-fmk, or FAM-LEHD-fmk to activated caspases in situ.
